Overview

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Status:
Terminated

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to confirm that tasquinimod used as maintenance therapy is active and tolerable in patients with metastatic castrate-resistant prostate cancer not progressing after a first chemotherapy with docetaxel.

Phase:

Phase 2

Details

Lead Sponsor:

Ipsen

Treatments:

Docetaxel